# Via Nova Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/via-nova-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.vianovatx.com
- Total disclosed funding: $5M
- Latest round: Series A (Aug 31, 2021)
- Investors on record: 1

## About

Founded in 2020 and based in California, US, Via Nova Therapeutics, Inc. operates as a biotechnology company for developing and discovering treatments for acute and subacute viral infections. The company was co-founded by Kelly Wong and Virologists Don Ganem. In September 2021, Via Nova Therapeutics raised USD 20 million in Series A funding led by Aditum Bio.

The company discovers and develops therapeutics for acute and subacute viral infections. The current programs at Via Nova were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses including influenza viruses, adenoviruses, and rhinoviruses as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. Via Nova Therapeutics targets fundamental mechanisms of viral replication and supports the discovery of novel therapeutics for other viral infections as well.

The company plans to use its funding from September 2021 to advance the development of preclinical antiviral programs in-licensed from Novartis.

## Funding rounds

- Series A, Aug 31, 2021, $5M — Aditum Bio

## Investors

- Aditum Bio (https://capitalatlas.ai/funds/aditum-bio) — Series A